Zacks Research Has Pessimistic Outlook of TMO Q1 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for shares of Thermo Fisher Scientific in a research report issued on Thursday, February 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $5.11 per share for the quarter, down from their previous forecast of $5.34. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s Q2 2025 earnings at $5.60 EPS, Q2 2026 earnings at $6.48 EPS, Q3 2026 earnings at $6.42 EPS and FY2027 earnings at $29.43 EPS.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%.

TMO has been the subject of a number of other research reports. Raymond James reiterated an “outperform” rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. UBS Group upped their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Royal Bank of Canada set a $693.00 target price on Thermo Fisher Scientific in a research note on Friday, January 31st. Finally, Scotiabank upped their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $656.86.

Thermo Fisher Scientific Stock Performance

TMO opened at $532.55 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The firm has a fifty day moving average price of $548.47 and a 200 day moving average price of $567.46. Thermo Fisher Scientific has a 1 year low of $493.30 and a 1 year high of $627.88. The stock has a market cap of $203.70 billion, a P/E ratio of 32.22, a P/E/G ratio of 2.99 and a beta of 0.77.

Institutional Trading of Thermo Fisher Scientific

A number of hedge funds and other institutional investors have recently modified their holdings of TMO. Legacy Investment Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at about $26,000. Peterson Financial Group Inc. acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $27,000. Barrett & Company Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. FPC Investment Advisory Inc. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $28,000. Finally, Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $29,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. This represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares in the company, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,125 shares of company stock valued at $11,231,699 in the last three months. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th will be paid a $0.43 dividend. The ex-dividend date is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.41%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.